Prior studies have demonstrated that CBX3 was overexpressed in GC [39], pancreatic cancer [21], HCC [33], osteosarcoma [34], CRC [35], prostate cancer [36] and non-small cell lung cancer (NSCLC) [40]. Here, CBX3 is linked to prostate carcinoma.